内容标题33

  • <tr id='O39Oq6'><strong id='O39Oq6'></strong><small id='O39Oq6'></small><button id='O39Oq6'></button><li id='O39Oq6'><noscript id='O39Oq6'><big id='O39Oq6'></big><dt id='O39Oq6'></dt></noscript></li></tr><ol id='O39Oq6'><option id='O39Oq6'><table id='O39Oq6'><blockquote id='O39Oq6'><tbody id='O39Oq6'></tbody></blockquote></table></option></ol><u id='O39Oq6'></u><kbd id='O39Oq6'><kbd id='O39Oq6'></kbd></kbd>

    <code id='O39Oq6'><strong id='O39Oq6'></strong></code>

    <fieldset id='O39Oq6'></fieldset>
          <span id='O39Oq6'></span>

              <ins id='O39Oq6'></ins>
              <acronym id='O39Oq6'><em id='O39Oq6'></em><td id='O39Oq6'><div id='O39Oq6'></div></td></acronym><address id='O39Oq6'><big id='O39Oq6'><big id='O39Oq6'></big><legend id='O39Oq6'></legend></big></address>

              <i id='O39Oq6'><div id='O39Oq6'><ins id='O39Oq6'></ins></div></i>
              <i id='O39Oq6'></i>
            1. <dl id='O39Oq6'></dl>
              1. <blockquote id='O39Oq6'><q id='O39Oq6'><noscript id='O39Oq6'></noscript><dt id='O39Oq6'></dt></q></blockquote><noframes id='O39Oq6'><i id='O39Oq6'></i>
                | EN

                恩瑞舒?:阿巴西普ㄨ註射液

                恩瑞舒?:阿巴西普註射液

                適應癥:

                中重度活性類◥風濕關節炎。


                 

                阿巴西普是中國首個及唯一獲批準銷售的CTLA4-Fc融合蛋白,全球自身免疫疾病領域第一個,也是∩目前唯一一種T細胞選擇性共刺激免疫@ 調節劑,不僅具有顯▽著的療效,還兼一座废弃工厂具良好的安全性和依從性。

                 

                它□ 能與抗原呈遞細胞表面的CD80和CD86結合,阻止了後者與T細胞表面CD28的相互作用▂,從而抑制T細胞激活,減少其下遊炎▲癥反應,繼而抑◥制關節損傷[1]

                針對ACPA陽性類▓風濕關節炎患者,恩瑞舒®有如◥下優勢:

                ?    是共刺激免疫調節劑≡,抑制免疫細胞過度活化,同時減少炎癥反應、有效治╳療類風濕關節炎

                ?    能更好改善ACPA陽性患者疾病活動度,具有更高的治療反∏應率(如ACR20、DAS28、EULAR應答);ACPA可以成為阿巴西普療效預測生物標誌[2][3]

                ?    長期使用感染住院風險低、結核病發生率低,安全性良好[4][5][6][7]

                 

                參考文獻:

                [1] Bonelli M, Scheinecker C. How does abatacept really work in rheumatoid arthritis[J]. Current opinion in rheumatology, 2018, 30(3): 295-300.

                [2] Alemao E, Postema R, Elbez Y, et al. Clinical and Experimental Rheumatology, 2019.

                [3] J. E. Gottenberg. et al. Arthritis & Rheumatology, Vol. 68, No. 6, June 2016, pp 13461352

                [4] Chen S K, Liao K P, Liu J, et al. Arthritis Care and Research, 2020, 72(1): 9-17.

                [5] Westhovens R, et al. Clin Exp Rheumatol, 2014, 32(4): 553-562.

                [6] Genovese M C, et al. The Journal of rheumatology, 2012, 39(8): 1546-1554.

                [7] Padovan M, et al.  Arthritis care & research, 2016, 68(6): 738-743.